Cas:25423-56-7 1,4,7,10-tetrathiacyclododecane manufacturer & supplier

Chemical Name:1,4,7,10-tetrathiacyclododecane

CAS.NO:25423-56-7

Synonyms:thiacrown ether {12}aneS4;Tetrathia-12-crown-4;[12]aneS4;MFCD00010829;1,4,7,10-Tetrathiadodecane;1,4,7,10-tetrtathia-cyclododecane;1,4,7,10-TETRATHIACYCLODODECANE

Molecular Formula:C₈H₁₆S₄

Molecular Weight:240.47300

HS Code:

Physical and Chemical Properties:

Melting point:226-228ºC(lit.)

Boiling point:160-162ºC0.5 mm Hg(lit.)

Density:1.14g/cm3

Index of Refraction:1.573

PSA:101.20000

Exact Mass:240.01300

LogP:2.93280

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like thiacrown ether {12}aneS4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4,7,10-TETRATHIACYCLODODECANE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4,7,10-TETRATHIACYCLODODECANE Use and application,thiacrown ether {12}aneS4 technical grade,usp/ep/jp grade.

Related News: Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. 1,4,7,10-tetrathiacyclododecane manufacturer A number of factors influenced the decision by the U.S. Centers for Disease Control and Prevention, including the COVID-19 pandemic, too few facilities to quarantine dogs safely and three recent incidents where rabies-infected dogs were brought into the country, CNN reported. 1,4,7,10-tetrathiacyclododecane supplier Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. 1,4,7,10-tetrathiacyclododecane vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 1,4,7,10-tetrathiacyclododecane factory Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.